- Paola Guglielmelli1,2,
- Giovanni Barosi3,
- Lisa Pieri1,2,
- Elisabetta Antonioli1,2,
- Alberto Bosi1,2 and
- Alessandro M. Vannucchi1,2⇓
- 1 Unità Funzionale di Ematologia, Dipartimento di Area Critica, Università degli Studi, Firenze
- 2 Istituto Toscano Tumori, Firenze
- 3 Unità di Epidemiologia Clinica, Centro per lo Studio della Mielofibrosi, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Correspondence: Alessandro M. Vannucchi, MD, Department of Hematology, University of Florence, 50134 Florence, Italy. Phone: international +39.055.7947688. Fax: international +39.055.7947688. E-mail:
The JAK2V617F mutational status and mutated allele burden were evaluated in 65 patients with post-poly-cythemia vera or post-essential thrombocythemia myelofibrosis (PPV/PET-MF). All PPV-MF patients harbored the mutation as compared to 27% of PET-MF. The V617F allele burden was higher in PPV- than in PET-MF (72% vs. 50%); 78% of the patients had greater than 50% V617F allele burden, supporting an adverse role of highest allele burden for MF transformation. In cases of PET-MF, no meaningful difference between JAK2V617F mutated and unmutated patients could be ascertained. Patients in the highest quartile of V617F allele burden were significantly older and had higher leukocyte and CD34+ cell count in peripheral blood than those in lower quartiles. There were 8 patients developing acute myeloid leukemia, who were equally distributed among JAK2V617F mutated or unmutated patients. We conclude that presence and burden of JAK2V617F mutation provide little clinically relevant information in patients with PPV/PET-MF.
Discovery of acquired recurrent molecular abnormalities in JAK2 (JAK2V617F mutation in exon 14 or mutations, insertions, deletions in exon 12) or MPL (mostly MPLW515L/K) has improved the diagnostic approach to the classic Philadelphia chromosome-negative chronic myeloproliferative disorders, defined as myeloproliferative neoplasms (MPNs) in the upcoming revised WHO classification.1 Virtually all patients with polycythemia vera (PV) have a mutation in JAK2, which is represented by the V617F allele in greater than 95% of cases; frequency of JAK2V617F mutation is 60–70% in patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF), while 10% of PMF patients2 and up to 8% of JAK2V617F unmutated ET3,4 patients harbor MPLW515L/K mutation. Presence of these molecular abnormalities constitutes a major diagnostic criteria in the 2008 WHO classification.1 A number of studies have addressed the relevance of V617F mutational status and of mutated allele burden on hematologic characteristics and clinical presentation. In patients with PV or ET, the amount of V617F allele measured in granulocytes was found to be positively associated with hemoglobin level and leukocyte count and inversely with platelet count; furthermore, the higher the mutational burden, the higher the risk of presenting aquagenic pruritus, of developing splenomegaly or suffering from cardiovascular events, and of requiring cytotoxic therapy.5 In PMF, results have been conflicting. An association of JAK2V617F mutational status with poorer overall survival was reported by Campbell et al.,6 but this has not been confirmed by others.7,8 A greater risk of developing large splenomegaly and leukemia was found in JAK2V617F mutated PMF patients included in a large study,8 while conversely a better overall and leukemia-free survival for patients presenting the highest V617F allele burden was reported in an analysis from the Mayo Clinic.9
On the other hand, information on patients with post-polycythemia vera (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) is scanty, and limited to a few small series. Passamonti et al. found a significantly higher V617F allele burden in 16 patients with PPV-MF in comparison to both pre-fibrotic and fully-fibrotic PMF patients,10 and allele burden was correlated to the number of circulating CD34+ cells. Tefferi et al. reported that patients with PPV-MF were more frequently JAK2V617F mutated than those with PET-MF (91% vs. 38.9%) and more frequently had an allele burden greater than 50% (found in 18% vs. 11.1% of the patients respectively).7 However, in these studies no attempt to correlate genotype with hematologic or clinical characteristics was made.
The aim of this study was to assess whether the JAK2V617F mutational status and/or allele burden had clinical and/or prognostic relevance for patients with PPV/PET-MF. Sixty-five patients, 43 with PPV-MF and 22 with PET-MF, were included; the diagnosis of evolution to MF from a pre-existing PV or ET was retrospectively verified in order to satisfy the recently adopted criteria from the IWG-MRT.11 Retrospective evaluation of archived data was approved by the local Ethical Committee. All patients had a stored DNA sample from purified granulocytes collected within nine months of the diagnosis of evolution to MF; analysis of JAK2V617F mutational status and mutated allele burden was performed as described.12
The median time elapsed from original diagnosis of PV or ET to myelofibrosis was 112 months (range 30–317) for PPV-MF and 137 months (29–266) for PET/MF. Median follow-up from the diagnosis of myelofibrosis evolution was 39 months for the whole cohort of patients, and it was not dissimilar for PPV-MF (40 months, range 6–275) and PET-MF (39 months, range 10–165) patients. During this period, 7 out of 8 patients in whom acute myeloid leukemia (AML) developed died at a median of 26 months (range 1–40) after leukemia diagnosis. Mean survival from diagnosis of myelofibrosis was 96 months (95% CI, 81–111) for the entire cohort of patients, and 99 months (95% CI, 83–115) and 83 months (95 CI, 53–112) for PPV-MF and PET-MF patients respectively.
The hematologic characteristics of the patients at diagnosis are reported in Table 1. A total of 49 patients (75.3%) harbored the JAK2V617F mutation. In agreement with previous reports,7,10 100% of PPV-MF patients were JAK2V617F mutated. On the contrary, the frequency of JAK2V617F mutation was 27.2% among PET-MF patients, significantly lower than that observed in a control group of 260 ET patients from our Institution (63.4%; p<0.01).13 This result argues for a dominant role of genetic mechanisms other than JAK2V617F in the MF transformation of ET. The median V617F allele burden in the entire population of patients was 73% ranging from 10 to 100%. The median value of V617F allele burden in PPV-MF was 72.0%, significantly higher than that observed in a group of 173 PV patients previously reported12 who showed a mean allele burden of 52%, confirming a role for the accumulation of mutated alleles in MF transformation of PV. Finally, in PET-MF the median allele burden was 57%, a value significantly greater than the 26% of a control group of ET patients from our Institution.13 This result suggests that accumulation of mutant V617F alleles is also a mechanism of evolution toward MF in JAK2V617F mutated ET patients.
Apart from a significantly lower platelet count (p=0.04) in JAK2V617F mutated patients, no other meaningful correlation with JAK2V617F mutational status could be ascertained (Table 1). The V617F mutated or unmutated patients were also comparable in terms of spleen size, incidence of thrombosis, incidence of major hemorrhages (2 patients in each group, all from previous ET), and the rate of AML transformation which occurred in 2/16 JAK2 unmutated and 6/49 JAK2V617F mutated patients (12.5% and 12.2% respectively) (data not shown). The correlation between V617F allele burden and clinical presentation and prognosis was also studied by dividing patients into quartiles of V617F allele distribution. We grouped together the first two quartiles because of the low number of patients included (Table 1), and we found that V617F allele burden was positively correlated with age, white blood cell count and circulating CD34+ cell count (all with a p value <0.05). However, there was no statistically significant correlation with clinical characteristics, i.e. spleen size, thrombosis, hemorrhages, nor with the rate of patients who evolved to AML (3 of whom were in the two first quartiles, one and 2 in the third and fourth quartile respectively).
To the best of our knowledge, this is the first study specifically addressing the clinical relevance of JAK2V617F mutation in patients who evolved to MF from a previous PV or ET. The data presented herein prompted us to conclude that neither the JAK2V617F mutational status nor the V617F allele burden seem to have relevance for disease phenotype or prognosis in this setting of patients. However, the relatively short follow-up might have prevented the discovery of correlations of JAK2V617F mutational status with clinical events occurring late in the history of these disorders, in particular for the evolution to AML. This will require larger patient series with a much longer observation.
Funding: the study was supported by Ministero della Università e Ricerca (COFIN 2006067001_003), Istituto Toscano Tumori, and institutional funds from Università di Firenze (ex-60%).
- Copyright© 2009 Ferrata Storti Foundation